Cargando…

Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, Nigeria

BACKGROUND: Vaccines are the most reliable alternative to elicit sterile immunity against malaria but their development has been hindered by polymorphisms and strain-specificity in previously studied antigens. New vaccine candidates are therefore urgently needed. Highly conserved Plasmodium falcipar...

Descripción completa

Detalles Bibliográficos
Autores principales: Ajibaye, Olusola, Osuntoki, Akinniyi A., Balogun, Emmanuel O., Olukosi, Yetunde A., Iwalokun, Bamidele A., Oyebola, Kolapo M., Hikosaka, Kenji, Watanabe, Yoh-ichi, Ebiloma, Godwin U., Kita, Kiyoshi, Amambua-Ngwa, Alfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945540/
https://www.ncbi.nlm.nih.gov/pubmed/31906953
http://dx.doi.org/10.1186/s12936-019-3096-0
_version_ 1783485198305853440
author Ajibaye, Olusola
Osuntoki, Akinniyi A.
Balogun, Emmanuel O.
Olukosi, Yetunde A.
Iwalokun, Bamidele A.
Oyebola, Kolapo M.
Hikosaka, Kenji
Watanabe, Yoh-ichi
Ebiloma, Godwin U.
Kita, Kiyoshi
Amambua-Ngwa, Alfred
author_facet Ajibaye, Olusola
Osuntoki, Akinniyi A.
Balogun, Emmanuel O.
Olukosi, Yetunde A.
Iwalokun, Bamidele A.
Oyebola, Kolapo M.
Hikosaka, Kenji
Watanabe, Yoh-ichi
Ebiloma, Godwin U.
Kita, Kiyoshi
Amambua-Ngwa, Alfred
author_sort Ajibaye, Olusola
collection PubMed
description BACKGROUND: Vaccines are the most reliable alternative to elicit sterile immunity against malaria but their development has been hindered by polymorphisms and strain-specificity in previously studied antigens. New vaccine candidates are therefore urgently needed. Highly conserved Plasmodium falciparum reticulocyte-binding protein homologue-5 (PfRH5) has been identified as a potential candidate for anti-disease vaccine development. PfRH5 is essential for erythrocyte invasion by merozoites and crucial for parasite survival. However, there is paucity of data on the extent of genetic variations on PfRH5 in field isolates of Plasmodium falciparum. This study described genetic polymorphisms at the high affinity binding polypeptides (HABPs) 36718, 36727, 36728 of PfRH5 in Nigerian isolates of P. falciparum. This study tested the hypothesis that only specific conserved B and T cell epitopes on PfRH5 HABPs are crucial for vaccine development. METHODS: One hundred and ninety-five microscopically confirmed P. falciparum samples collected in a prospective cross-sectional study of three different populations in Lagos, Nigeria. Genetic diversity and haplotype construct of Pfrh5 gene were determined using bi-directional sequencing approach. Tajima’s D and the ratio of nonsynonymous vs synonymous mutations were utilized to estimate the extent of balancing and directional selection in the pfrh5 gene. RESULTS: Sequence analysis revealed three haplotypes of PfRH5 with negative Tajima’s D and dN/dS value of − 1.717 and 0.011 ± 0.020, respectively. A single nucleotide polymorphism, SNP (G → A) at position 608 was observed, which resulted in a change of the amino acid cysteine at position 203 to tyrosine. Haplotype and nucleotide diversities were 0.318 ± 0.016 and 0.0046 ± 0.0001 while inter-population genetic differentiation ranged from 0.007 to 0.037. Five polypeptide variants were identified, the most frequent being KTKYH with a frequency of 51.3%. One B-cell epitope, 151 major histocompatibility complex (MHC) class II T-cell epitopes, four intrinsically unstructured regions (IURs) and six MHC class I T-cell epitopes were observed in the study. Phylogenetic analysis of the sequences showed clustering and evidence of evolutionary relationship with 3D7, PAS-2 and FCB-2 RH5 sequences. CONCLUSIONS: This study has revealed low level of genetic polymorphisms in PfRH5 antigen with B- and T-cell epitopes in intrinsically unstructured regions along the PfRH5 gene in Lagos, Nigeria. A broader investigation is however required in other parts of the country to support the possible inclusion of PfRH5 in a cross-protective multi-component vaccine.
format Online
Article
Text
id pubmed-6945540
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69455402020-01-07 Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, Nigeria Ajibaye, Olusola Osuntoki, Akinniyi A. Balogun, Emmanuel O. Olukosi, Yetunde A. Iwalokun, Bamidele A. Oyebola, Kolapo M. Hikosaka, Kenji Watanabe, Yoh-ichi Ebiloma, Godwin U. Kita, Kiyoshi Amambua-Ngwa, Alfred Malar J Research BACKGROUND: Vaccines are the most reliable alternative to elicit sterile immunity against malaria but their development has been hindered by polymorphisms and strain-specificity in previously studied antigens. New vaccine candidates are therefore urgently needed. Highly conserved Plasmodium falciparum reticulocyte-binding protein homologue-5 (PfRH5) has been identified as a potential candidate for anti-disease vaccine development. PfRH5 is essential for erythrocyte invasion by merozoites and crucial for parasite survival. However, there is paucity of data on the extent of genetic variations on PfRH5 in field isolates of Plasmodium falciparum. This study described genetic polymorphisms at the high affinity binding polypeptides (HABPs) 36718, 36727, 36728 of PfRH5 in Nigerian isolates of P. falciparum. This study tested the hypothesis that only specific conserved B and T cell epitopes on PfRH5 HABPs are crucial for vaccine development. METHODS: One hundred and ninety-five microscopically confirmed P. falciparum samples collected in a prospective cross-sectional study of three different populations in Lagos, Nigeria. Genetic diversity and haplotype construct of Pfrh5 gene were determined using bi-directional sequencing approach. Tajima’s D and the ratio of nonsynonymous vs synonymous mutations were utilized to estimate the extent of balancing and directional selection in the pfrh5 gene. RESULTS: Sequence analysis revealed three haplotypes of PfRH5 with negative Tajima’s D and dN/dS value of − 1.717 and 0.011 ± 0.020, respectively. A single nucleotide polymorphism, SNP (G → A) at position 608 was observed, which resulted in a change of the amino acid cysteine at position 203 to tyrosine. Haplotype and nucleotide diversities were 0.318 ± 0.016 and 0.0046 ± 0.0001 while inter-population genetic differentiation ranged from 0.007 to 0.037. Five polypeptide variants were identified, the most frequent being KTKYH with a frequency of 51.3%. One B-cell epitope, 151 major histocompatibility complex (MHC) class II T-cell epitopes, four intrinsically unstructured regions (IURs) and six MHC class I T-cell epitopes were observed in the study. Phylogenetic analysis of the sequences showed clustering and evidence of evolutionary relationship with 3D7, PAS-2 and FCB-2 RH5 sequences. CONCLUSIONS: This study has revealed low level of genetic polymorphisms in PfRH5 antigen with B- and T-cell epitopes in intrinsically unstructured regions along the PfRH5 gene in Lagos, Nigeria. A broader investigation is however required in other parts of the country to support the possible inclusion of PfRH5 in a cross-protective multi-component vaccine. BioMed Central 2020-01-06 /pmc/articles/PMC6945540/ /pubmed/31906953 http://dx.doi.org/10.1186/s12936-019-3096-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ajibaye, Olusola
Osuntoki, Akinniyi A.
Balogun, Emmanuel O.
Olukosi, Yetunde A.
Iwalokun, Bamidele A.
Oyebola, Kolapo M.
Hikosaka, Kenji
Watanabe, Yoh-ichi
Ebiloma, Godwin U.
Kita, Kiyoshi
Amambua-Ngwa, Alfred
Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, Nigeria
title Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, Nigeria
title_full Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, Nigeria
title_fullStr Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, Nigeria
title_full_unstemmed Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, Nigeria
title_short Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, Nigeria
title_sort genetic polymorphisms in malaria vaccine candidate plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in lagos, nigeria
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945540/
https://www.ncbi.nlm.nih.gov/pubmed/31906953
http://dx.doi.org/10.1186/s12936-019-3096-0
work_keys_str_mv AT ajibayeolusola geneticpolymorphismsinmalariavaccinecandidateplasmodiumfalciparumreticulocytebindingproteinhomologue5amongpopulationsinlagosnigeria
AT osuntokiakinniyia geneticpolymorphismsinmalariavaccinecandidateplasmodiumfalciparumreticulocytebindingproteinhomologue5amongpopulationsinlagosnigeria
AT balogunemmanuelo geneticpolymorphismsinmalariavaccinecandidateplasmodiumfalciparumreticulocytebindingproteinhomologue5amongpopulationsinlagosnigeria
AT olukosiyetundea geneticpolymorphismsinmalariavaccinecandidateplasmodiumfalciparumreticulocytebindingproteinhomologue5amongpopulationsinlagosnigeria
AT iwalokunbamidelea geneticpolymorphismsinmalariavaccinecandidateplasmodiumfalciparumreticulocytebindingproteinhomologue5amongpopulationsinlagosnigeria
AT oyebolakolapom geneticpolymorphismsinmalariavaccinecandidateplasmodiumfalciparumreticulocytebindingproteinhomologue5amongpopulationsinlagosnigeria
AT hikosakakenji geneticpolymorphismsinmalariavaccinecandidateplasmodiumfalciparumreticulocytebindingproteinhomologue5amongpopulationsinlagosnigeria
AT watanabeyohichi geneticpolymorphismsinmalariavaccinecandidateplasmodiumfalciparumreticulocytebindingproteinhomologue5amongpopulationsinlagosnigeria
AT ebilomagodwinu geneticpolymorphismsinmalariavaccinecandidateplasmodiumfalciparumreticulocytebindingproteinhomologue5amongpopulationsinlagosnigeria
AT kitakiyoshi geneticpolymorphismsinmalariavaccinecandidateplasmodiumfalciparumreticulocytebindingproteinhomologue5amongpopulationsinlagosnigeria
AT amambuangwaalfred geneticpolymorphismsinmalariavaccinecandidateplasmodiumfalciparumreticulocytebindingproteinhomologue5amongpopulationsinlagosnigeria